We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-10.34%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.95B
AUM Growth
-$1.05B
Cap. Flow
+$64.3M
Cap. Flow %
1.08%
Top 10 Hldgs %
34.22%
Holding
172
New
36
Increased
33
Reduced
28
Closed
30

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$126M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$126M
3
PASG icon
Passage Bio
PASG
+$109M
4
PFE icon
Pfizer
PFE
+$108M
5
CNC icon
Centene
CNC
+$81M

Top Sells

Rank Stock Value
1
THOR
Synthorx, Inc. Common Stock
THOR
+$372M
2
ARQL
Arqule Inc
ARQL
+$99.8M
3
DHR icon
Danaher
DHR
+$98.1M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$79.2M
5
INSP icon
Inspire Medical Systems
INSP
+$74M

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Financials 1.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$370M 6.22%
3,287,400
-55,700
-2% -$7.24M
TCDA
2
DELISTED
Tricida, Inc. Common Stock
TCDA
$212M 3.55%
9,614,280
– –
ALEC icon
3
Alector
ALEC
$169M
$201M 3.38%
8,327,691
-2,660,253
-24% -$67.8M
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$200M 3.36%
7,406,307
– –
MRK icon
5
Merck
MRK
$326B
$199M 3.35%
2,713,377
+665,480
+32% +$52.3M
ALXN
6
DELISTED
Alexion Pharmaceuticals
ALXN
$186M 3.13%
2,071,385
+408,800
+25% +$40.1M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$124B
$175M 2.95%
737,400
-45,700
-6% -$10.5M
PRVL
8
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$168M 2.83%
13,822,463
– –
IOVA icon
9
Iovance Biotherapeutics
IOVA
$2.1B
$166M 2.79%
5,548,326
– –
BSX icon
10
Boston Scientific
BSX
$68.5B
$158M 2.66%
4,847,300
+172,500
+4% +$6.74M
BIIB icon
11
Biogen
BIIB
$30.4B
$152M 2.55%
480,400
+415,900
+645% +$126M
ARQT icon
12
Arcutis Biotherapeutics
ARQT
$3.55B
$139M 2.34%
+4,673,850
New +$126M
BMY icon
13
Bristol-Myers Squibb
BMY
$130B
$138M 2.32%
2,474,800
+774,800
+46% +$47.4M
TPTX
14
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$123M 2.06%
2,745,327
– –
GILD icon
15
Gilead Sciences
GILD
$167B
$110M 1.85%
1,471,100
+1,145,000
+351% +$79.1M
PASG icon
16
Passage Bio
PASG
$14.7M
$110M 1.84%
+348,145
New +$109M
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$109M 1.84%
1,423,300
+82,700
+6% +$7.42M
ETNB
18
DELISTED
89bio
ETNB
$101M 1.7%
4,004,442
– –
NXTC icon
19
NextCure
NXTC
$22.1M
$100M 1.69%
225,918
– –
NBIX icon
20
Neurocrine Biosciences
NBIX
$18.4B
$100M 1.68%
1,155,015
+219,045
+23% +$21.4M
NTRA icon
21
Natera
NTRA
$36.1B
$99.9M 1.68%
3,347,000
+906,387
+37% +$30.3M
PFE icon
22
Pfizer
PFE
$144B
$98.3M 1.65%
+3,174,753
New +$108M
DXCM icon
23
DexCom
DXCM
$28.9B
$91M 1.53%
1,352,000
+412,400
+44% +$25.7M
EHTH icon
24
eHealth
EHTH
$43.2M
$89.9M 1.51%
638,558
-473,356
-43% -$54.3M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.63B
$88.3M 1.48%
902,449
+136,400
+18% +$15.6M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2020 Portfolio in Review

As of Q1 2020, OrbiMed held 172 positions worth $5.95B, down 15% from $7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed's Q1 2020 filing shows 36 new, 33 increased, 28 reduced and 30 closed positions. Its largest new stake was Arcutis Biotherapeutics: 4,673,850 shares worth $139M. The largest sale was Synthorx, Inc. Common Stock, an estimated $372M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q1 2020 buy was Arcutis Biotherapeutics: 4,673,850 shares worth $139M.
  • OrbiMed added most to Biogen in Q1 2020, an estimated $126M increase.
  • OrbiMed's biggest Q1 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $79.2M.
  • OrbiMed fully exited Synthorx, Inc. Common Stock in Q1 2020, selling an estimated $372M.
  • OrbiMed's ten largest holdings make up 34% of its $5.95B portfolio in Q1 2020.
  • OrbiMed opened 36 new positions and closed 30 in Q1 2020.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $5.95B.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.